Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Sucampo Pharmaceuticals, Inc. | a50643488ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 28, 2013
|
Sucampo Pharmaceuticals, Inc.
|
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
001-33609
|
30-0520478
|
|
(State or Other Juris-
diction of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
4520 East-West Highway, 3rd Floor
Bethesda, Maryland
|
20814
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (301) 961-3400
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On May 28, 2013, Sucampo Pharmaceuticals, Inc. (the “Company”) entered into a consulting agreement with Gayle R. Dolecek, P.D., who resigned from his position as Executive Advisor, Research and Development Affairs of the Company and his employment at the Company, effective May 31, 2013. He will remain as a class 2 member of the board of directors of the Company.
Under the terms of the consulting agreement, Dr. Dolecek will, in addition to his services as a board member, provide research and development services to the Company from June 1, 2013 until May 31, 2014 at a certain number of hours per month and at a fixed amount of $170,000.
Exhibit Consulting Agreement.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit relating to Item 1.01 shall be deemed to be furnished, and not filed:
99.1 Consulting Agreement with Gayle R. Dolecek, P.D.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SUCAMPO PHARMACEUTICALS, INC. | |||
|
Date: May 31, 2013
|
By: | /s/ Thomas J. Knapp | |
| Name: |
Thomas J. Knapp
|
||
| Title: |
EVP, Chief Legal Officer and Corporate Secretary
|
||